EU/3/19/2172

Table of contents

About

On 28 June 2019, orphan designation EU/3/19/2172 was granted by the European Commission to FGK Representative Service GmbH, Germany, for gaboxadol monohydrate for the treatment of Angelman syndrome.

Key facts

Active substance
Gaboxadol monohydrate
Disease / condition
Treatment of Angelman syndrome
Date of first decision
28/06/2019
Outcome
Positive
EU designation number
EU/3/19/2172

Sponsor's contact details

FGK Representative Service GmbH
Heimeranstrasse 35
80339 Munich
Germany
Tel. +49 8989 311922
E-mail: info@fgk-rs.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating